ERBB2 and breast cancer: Surprisingly, in 159 HR-positive Her2-positive BC, the endocrine therapy uses decreased with the increasing age group, with a lower rate in patients more than 80 years old (85.1% versus 93.3% and 95.8% in patients 70-74 years and 75-80 years, respectively) approaching statistical significance (p=0.052) (Table 1).